Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19: the SAVE open-label, non-randomized single-arm trial Brief Description SAVE is an open non-randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by the biomarker
Completed study Official Study Title Efficiency in management of organ dysfunction associated with infection by the novel SARS-Cov-2 virus through A PErsonalized immunotherapy approach Brief Description ESCAPE is an open non-randomized clinical trial aiming to the personalized therapy of patients with COVID-19. Using biomarkers, enrolled patients are receiving treatment with intravenous anakinra or intravenous
Completed study Official Study Title A Personalized Randomized Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis (PROVIDE) Brief Description PROVIDE is a randomized clinical trial aiming to the personalized therapy of patients at septic shock. Using biomarkers, enrolled patients are randomized through a double-dummy approach to immunotherapy or placebo
Vassiliki Tzanetakou, Theodora Kanni, Sophia Giatrakou, Alexandros Katoulis, Evangelia Papadavid, Mihai G Netea, Charles A Dinarello, Jos W M van der Meer, Dimitrios Rigopoulos, Evangelos J. Giamarellos-Bourboulis JAMA Dermatology 2016 Jan;152(1):52-59 DOI: 10.1001/jamadermatol.2015.3903View article 🡇 Funding This study was supported in part by the Interleukin Foundation, by grant AI-15614 from the National Institutes
Completed study Official Study Title A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa Details Status: Completed Study Type: Interventional (Clinical Trial) Study phase: II Study sites: 2 sites in Greece Actual enrolment: 20 participants ClinicalTrials.gov Identifier: NCT01558375 EudraCT number: 2011-005145-12 National Organization for